- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00384657
Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
The Effects of Intravenous Iron Therapy for Anemia Correction in Patients With Severe Chronic Heart Failure and Concomitant Moderate Chronic Kidney Disease
Recently, growing body of evidence support the finding that anemia frequently occurs in patients with chronic heart failure (CHF). Chronic kidney disease (CKD), as well, is highly prevalent among heart failure patients, and both anemia and CKD are independently associated with increased mortality. A vicious circle is established with CHF causing both chronic renal insufficiency and anemia, and CKD further aggravating anemia which, in turn, worsens CHF and so on. Treatment of the anemia breaks this circle and improves the quality of life, cardiac and renal functions in patients with severe CHF.
Intravenous iron alone was proved to allow the maintenance of target hematocrit in one-third of chronic renal failure predialysis patients.
Based on these considerations, intravenous iron for anemia in patients with CHF and moderate CKD would represent a reasonable therapeutic approach.
The aim of the trial is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with CHF NYHA III class and concomitant moderate CKD.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
Intravenous iron administration in CHF patients with absolute or functional iron deficiency could correct their anemia, thus improving cardiac function judged by ejection fraction and NYHA functional class. If true, enhancement of cardiac output will increase oxygen delivery to tissues, including renal cortex. This might improve the renal functions and slow the rate of progression of CKD reflected by the slope of decline in glomerular filtration rate (GFR).
Since erythropoietin synthesis is located in peritubular fibroblasts from outer renal cortex, which is the most affected area during chronic hypoxia, increasing renal blood flow after anemia correction is expected to restore optimal erythropoietin production and normalize plasma Epo levels.
The primary objective is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with chronic heart failure NYHA III class and concomitant moderate chronic kidney disease.
The secondary objectives are to determine if the correction of anemia in these patients affects the cardiac function, the rate of progression of CKD and the plasma erythropoietin levels.
The study will be conducted in accordance with the Declaration from Helsinki and Tokyo, with the amendments from Venice (1983), after the approval by the local ethics committee.
The total observation period will be of 28 weeks, with a pre-study phase (selection, randomization of subjects) 4 weeks.The study period will last 24 weeks, with a possible extension to 48 weeks, depending on the results of this first phase.
200 anemic patients with chronic heart failure class NYHA III and concomitant stage 3 chronic kidney disease will be enrolled, after obtaining their written informed consent.
All patients will be evaluated for the inclusion and exclusion criteria at enrollment and at each visit during the pre-study phase. Only patients fulfilling all the requested criteria at all evaluation moments will be enrolled. The enrolled subjects will be centrally randomly assigned in a 1:1 ratio into two study groups.
Group I (treatment group): Subjects assigned to this group will receive intravenous iron (ferric sucrose product Venofer® 2%, 5mL/ampoule) in a starting dose of 200mg (2 ampoules) diluted in 150mL 0.9% NaCl solution, over 60 minutes, once a week for the first four administrations, and then every other week until hemoglobin levels reach 12g/dL. Then, iron dose will be adjusted to 1 ampoule at 2-4 weeks interval, as needed to maintain these levels with serum ferritin ≤500ng/mL.
Iron administration will be discontinued if serum ferritin will exceed 500ng/mL, and will be restarted with a reduced dosage (1 ampoule at every 2-4 weeks) once serum ferritin decrease below this value.
Conventional treatment for CHF will be continued as needed. Group II (control group): Subjects assigned to this group will continue their conventional treatment for CHF as needed, without iron supplementation.
No other anti-anemic medication will be administered in either group during the study period.
Subject's visits will take place at two weeks intervals in the first 12 weeks of the study phase and at 4 weeks apart thereafter. At each visit will be recorded, according to the schedule, data concerning physical examination, including signs of CHF, hematological and iron status, renal function, concomitant medication and adverse events.
Parameters recorded at the time of first iron administration will serve as baseline determination.
The completion of the study will be declared when 200 subjects will complete the whole observation period, according to the above protocol.
Typ studiów
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Bucharest, Rumunia, 010731
- "Dr Carol Davila" Teaching Hospital of Nephrology
-
Bucharest, Rumunia
- "Caritas" Teaching Hospital, Cardiology Department
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- persistent severe CHF: functional class NYHA III (marked limitation of physical activity - comfortable at rest, but less than ordinary activity results in shortness of breath and/or fatigue16); left ventricular ejection fraction (echocardiography) less than 40%; functional and systolic dysfunction criteria must be stable at two different examinations one month apart;
- stable stage 3 chronic kidney disease: estimated GFR between 30-59mL/min/1.73m2 (mean value of three measurements within the last 8 weeks, separated from each other by at least one week); stable renal function (at least three different measurements within the past 8 weeks, separated from each other by at least one week; the difference between the highest and the lowest value should be less than 5mL/min/1.73m2)
- mild to moderate anemia: hemoglobin levels < 12g/dL (mean value of three measurements within the last 8 weeks, separated from each other by at least one week) and stable (at least three measurements within the last 8 weeks; the difference between the highest and the lowest value should be less than 1.5g/dL);
- iron deficiency: absolute (serum ferritin < 100ng/mL) or functional (serum ferritin 100-300ng/mL and transferrin saturation < 20%)
Exclusion Criteria:
- evidence of active gastrointestinal or genital tract bleeding
- folate or vitamin B12 deficiency
- hypothyroidism
- hemolytic anemia
- any primary kidney diseases (glomerulonephritis, interstitial nephritis, cystic diseases)
- systemic diseases with renal involvement (lupus erythematosus, vasculitis, amyloidosis)
- renal artery stenosis (>70% lumen reduction)
- diabetic nephropathy
- severe malnutrition (SGA score C or lower)
- active liver diseases
- infectious conditions
- malignancies
- C-reactive protein > 12 mg/L
- severe anemia (< 8.5g/dL)
- blood transfusions in the preceding two months
- iron therapy in the preceding three months
- concomitant erythropoietin therapy
- severe arterial hypertension (systolic BP >190 mm Hg and/or diastolic BP >115 mm Hg)
- recent history (less than 3 months) of acute coronary syndrome
- recent (less than 1 month) PCI
- recent (less than 1 month) CABG surgery
- active myocarditis
- active endocarditis
- more than mild valvar stenosis
- more than moderate valvar (mitral or aortic) regurgitation
- uncontrolled haemodynamically relevant atrial fibrillation/flutter
- hypertrophic cardiomyopathy
- acute and/or chronic pericarditis
- cor pulmonale
- participation in another study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Group I
iv iron sucrose
|
Patients in Group I will receive iv iron sucrose, as described in the study protocol. Patient in Group II will receive conventional treatment for chronic heart failure.
Inne nazwy:
|
Brak interwencji: Group II
Patients will receive conventional treatment of Chronic Heart Failure.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
percentage of patients with increased ejection fraction
Ramy czasowe: 12 months
|
12 months
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Przyjęcia szpitalne
Ramy czasowe: 12 miesięcy
|
12 miesięcy
|
the need for blood transfusions during the study period
Ramy czasowe: 12 months
|
12 months
|
serum ferritin level
Ramy czasowe: 12 months
|
12 months
|
transferrin saturation
Ramy czasowe: 12 months
|
12 months
|
radial myocardial velocities
Ramy czasowe: 12 months
|
12 months
|
right ventricular function
Ramy czasowe: 12 months
|
12 months
|
global diastolic function
Ramy czasowe: 12 months
|
12 months
|
left ventricular mass index
Ramy czasowe: 12 months
|
12 months
|
major cardiovascular events (myocardial infarction, acute pulmonary edema, stroke)
Ramy czasowe: 12 months
|
12 months
|
death of the patient (all causes deaths, cardiac deaths)
Ramy czasowe: 12 months
|
12 months
|
slope of GFR change
Ramy czasowe: 12 months
|
12 months
|
"death" of the kidney (initiation of renal replacement therapy)
Ramy czasowe: 12 months
|
12 months
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Gabriel Mircescu, Professor, Dr Carol Davila Teaching Hospital of Nephrology
- Główny śledczy: Tiberiu Nanea, Professor, "Caritas" Teaching Hospital, Bucharest
- Główny śledczy: Liliana Garneata, MD, PhD, Dr Carol Davila Teaching Hospital of Nephrology Bucharest
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- AWG_06_01
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Niedokrwistość
-
UCSF Benioff Children's Hospital OaklandNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Medical... i inni współpracownicyZakończonyAnemia sierpowata | Talasemia | Anemia Diamonda-BlackfanaZjednoczone Królestwo, Stany Zjednoczone, Niemcy
-
Jason WilsonRekrutacyjny
-
Amy TangPfizerRekrutacyjnyAnemia sierpowata u dzieciStany Zjednoczone
-
Stanford UniversityUniversity of Alabama at Birmingham; University of MinnesotaZakończonyAnemia sierpowata | Talasemia | Anemia Diamonda-BlackfanaStany Zjednoczone
-
Global Health Uganda LTDEunice Kennedy Shriver National Institute of Child Health and Human Development... i inni współpracownicyAktywny, nie rekrutujący
-
Al-Neelain UniversityUniversity of KhartoumNieznany
-
Centre Hospitalier Intercommunal CreteilRekrutacyjnyAnemia sierpowatokrwinkowa nr z kryzysemFrancja
-
Essen BiotechJeszcze nie rekrutacjaAnemia sierpowata | Anemia Sierpowata Z KryzysemChiny
-
University of Mississippi Medical CenterUniversity of Alabama at BirminghamRekrutacyjnyAnemia sierpowata u dzieciStany Zjednoczone
-
Brown UniversityNational Heart, Lung, and Blood Institute (NHLBI); NovartisRekrutacyjnyAnemia sierpowata | Anemia sierpowata u dzieciAngola
Badania kliniczne na iron sucrose
-
PharmaLinea Ltd.ZakończonyNiedobór żelaza | Niedokrwistość z niedoboru żelazaSłowenia
-
University of LouisvilleZakończonyNiewydolność nerek, przewlekła | Niedokrwistość w przewlekłej chorobie nerek | Anemia, niedobór żelazaStany Zjednoczone
-
Children's Hospital of PhiladelphiaLucky Iron FishZakończonyNiedobór żelaza | Niedokrwistość z niedoboru żelazaRepublika Dominikany
-
Ain Shams UniversityZakończonyHematologiczne powikłania ciążyEgipt
-
University of Mary Hardin-BaylorChemiNutraZakończonyNiedobór żelazaStany Zjednoczone
-
Ahmadu Bello University Teaching HospitalRekrutacyjnyBezpłodność, kobieta | Zapalenie narządów miednicy mniejszejNigeria
-
University of Maryland, BaltimoreZakończonyNie-anemiczny niedobór żelazaStany Zjednoczone
-
Biotyx Medical (Shenzhen) Co., Ltd.Aktywny, nie rekrutujący
-
University of British ColumbiaUniversity of Guelph; NCHADS - Ministry of Health of CambodiaZakończonyAnemia, niedobór żelaza | Niedokrwistość | HemoglobinopatieKambodża
-
Emory UniversityInternational Food Policy Research InstituteZakończony